Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ROS1-positive non-small cell lung cancer (NSCLC): biology, diagnostics, therapeutics and resistance

6 Jun 2022

Abstract excerpt

ROS1 is a proto-oncogene encoding a receptor tyrosine protein kinase (RTK), homologous to the v - Ros sequence of University of Manchester tumours virus 2 (UR2) sarcoma virus, whose ligands are still being investigated. ROS1 fusion genes have been identified in various types of tumours. As an oncoprotein, it promotes cell proliferation, activation and cell cycle progression by activating downstream signalling...

Topics

Join the communities discussing this publication.

Cytokine Signaling Pathways and Interactions
Lung Cancer Treatments and Mutations
PI3K/AKT/mTOR signaling in cancer

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 35658765
DOI: 10.1080/1061186x.2022.2085730

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ROS1-positive non-small cell lung cancer (NSCLC): biology, diagnostics, therapeutics and resistancePMID 35658765Read ↗

ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to DateSemantic proximity Read ↗

Progress of non-small-cell lung cancer with ROS1 rearrangementSemantic proximity Read ↗

ROS1-rearranged Non-small Cell Lung Cancer.Semantic proximity Read ↗

Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted TherapiesSemantic proximity Read ↗

Clinicopathologic and molecular characteristics of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients.Semantic proximity Read ↗

Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance.Semantic proximity Read ↗

Survival of Patients with Advanced Non-Small Cell Lung Cancer Harboring Different ROS1 Fusion Subtypes: A Real-World StudySemantic proximity Read ↗

New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1).Semantic proximity Read ↗

Deepening the Knowledge of ROS1 Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant AlterationsSemantic proximity Read ↗

ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy.Semantic proximity Read ↗

Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma.Semantic proximity Read ↗

Importance of ROS1 fene fusions in non-small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.